haloperidol
Trade name: haldol
Approved
Apr 12, 1967
Haloperidol is a phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and Tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of Huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. Haloperidol also exerts sedative and antiemetic activity. Haloperidol principal pharmacological effects are similar to those of piperazine-derivative phenothiazines. The drug has action at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. The precise mechanism whereby the therapeutic effects of haloperidol are produced is not known, but the drug appears to depress the CNS at the subcortical level of the brain, midbrain, and brain stem reticular formation. Haloperidol seems to inhibit the ascending reticular activating system of the brain stem (possibly through the caudate nucleus), thereby interrupting the impulse between the diencephalon and the cortex. The drug may antagonize the actions of glutamic acid within the extrapyramidal system, and inhibitions of catecholamine receptors may also contribute to haloperidol's mechanism of action. Haloperidol may also inhibit the reuptake of various neurotransmitters in the midbrain, and appears to have a strong central antidopaminergic and weak central anticholinergic activity. The drug produces catalepsy and inhibits spontaneous motor activity and conditioned avoidance behaviours in animals. The exact mechanism of antiemetic action of haloperidol has also not been fully determined, but the drug has been shown to directly affect the chemoreceptor trigger zone (CTZ) through the blocking of dopamine receptors in the CTZ. Haloperidol is marketed under the trade name Haldol among others. — NCATS
Clinical trial activity
140 trials · 176 clinical orgs · 51 marketing orgs
Earliest trial started Apr 1, 1987 (NCT00946491)
Timeline
1960s
- Apr 12, 1967
Johnson and Johnson — Earliest FDA Approval
- Apr 12, 1967
Johnson and Johnson — NDA Organization
- Apr 12, 1967
Johnson and Johnson — Marketing Organization
1970s
- May 18, 1971
Johnson and Johnson — NDA Secondary Org
1980s
- Jun 10, 1986
Mylan — Marketing Organization
- Nov 3, 1986
Vintage — Marketing Organization
- Nov 3, 1986
Strides Pharma Science — Marketing Organization
- Nov 3, 1986
Puracap Pharmaceutical — Marketing Organization
- Nov 17, 1986
Sandoz — Marketing Organization
- Nov 17, 1986
Chartwell Pharmaceuticals — Marketing Organization
- Dec 4, 1986
Duramed Research — Marketing Organization
- Jan 1, 1987
- Jan 2, 1987
ANDA Repository — Marketing Organization
- Jan 2, 1987
Innogenix — Marketing Organization
- Jan 20, 1987
Abraxis — Marketing Organization
- Feb 17, 1987
Cycle Pharmaceuticals Ltd. — Marketing Organization
- Feb 17, 1987
AiPing Pharm Inc — Marketing Organization
- Feb 17, 1987
Sciegen Pharmaceticals — Marketing Organization
- Mar 6, 1987
Watson Pharmaceuticals — Marketing Organization
- Aug 25, 1987
Teva — Marketing Organization
- Apr 12, 1988
Hikma — Marketing Organization
1990s
- Feb 25, 1993
Marsam Pharmaceuticals — Marketing Organization
- Feb 26, 1993
Pharmaceutical Associates — Marketing Organization
- Sep 28, 1993
Lannett Company, Inc. — Marketing Organization
- Nov 2, 1995
Actavis — Marketing Organization
- Dec 19, 1997
Fresenius — Marketing Organization
- Jan 30, 1998
West-Ward Pharmaceutical — Marketing Organization
- Jan 1, 1999
Earliest Phase 3 Sponsor(trial)
2000s
- Feb 9, 2000
Hospira — Marketing Organization
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
- Aug 25, 2004
Gland Pharma Ltd — Marketing Organization
- Aug 25, 2004
Baxalta — Marketing Organization
- Sep 29, 2004
Fosun — Marketing Organization
- Jun 24, 2005
Novartis — Marketing Organization
- Nov 29, 2007
Zydus Discovery DMCC — Marketing Organization
2010s
- Sep 2, 2011
Sagent Pharmaceuticals, Inc. — Marketing Organization
- Sep 6, 2017
Akorn, Inc. — Marketing Organization
- Sep 6, 2017
Epic Pharma Llc — Marketing Organization
- Jul 3, 2018
Somerset Pharmaceuticals — Marketing Organization
2020s
- Jan 8, 2020
Appco Pharma — Marketing Organization
- Jan 8, 2020
Upsher-Smith Laboratories — Marketing Organization
- Jul 26, 2021
Meitheal — Marketing Organization
- Jul 1, 2022
AbbVie — Marketing Organization
- Nov 18, 2022
MSN Laboratories — Marketing Organization
- May 23, 2023
Mankind Pharma — Marketing Organization
- Jan 31, 2024
Rubicon Research — Marketing Organization
- Apr 19, 2024
Aurobindo Pharma — Marketing Organization
- May 13, 2025
Caplin Point Laboratories — Marketing Organization
Indications
Studied for
- Abdominal Pain · Phase 4
- Aggression · Phase 4
- Akathisia, Drug-Induced · Phase 2
- Allergy and Immunology · Phase 4
- Alzheimer Disease · Phase 4
- Antipsychotic Agents · Phase 2/Phase 3
- Anxiety · Phase 4
- Anxiety Disorders · Phase 3
- Back Pain · Phase 4
- Behavior · Phase 4
- Bipolar Disorder · Phase 4
- Cannabinoids · Phase 3
- Cannabis · Phase 4
- Cholecystectomy, Laparoscopic · Phase 2
- Chronic Pain · Phase 4
- Cognition · Phase 4
- Cognition Disorders · Phase 3
- Cognitive Aging · Phase 2/Phase 3
- Cognitive Dysfunction · Phase 4
- Confusion · Phase 3
- Critical Care · Phase 2
- Critical Illness · Phase 3
- Delirium · Phase 4
- Dementia · Phase 4
- Depression · Phase 4
- Disease · Phase 3
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Epilepsy · Phase 2/Phase 3
- Gambling · Phase 2
- Gastroparesis · Phase 4
- General Surgery · Phase 3
- Glioblastoma · Phase 2
- Haloperidol · Phase 3
- Headache · Phase 4
- Healthy Volunteers · Phase 4
- Hematopoietic Stem Cell Transplantation · Phase 4
- Hip Fractures · Phase 3
- Huntington Disease · Phase 1
- Insulin · Phase 4
- Intellectual Disability · Phase 2
- Ketamine · Phase 2
- Labor Onset · Phase 4
- Labor Pain · Phase 4
- Labor Stage, First · Phase 4
- Laparoscopy · Phase 4
- Levodopa · Phase 1
- Liver · Phase 4
- Medication Adherence · Phase 3
- Mental Disorders · Phase 3
- Mental Health · Phase 3
- Methamphetamine · Phase 2
- Migraine Disorders · Phase 4
- Mood Disorders · Phase 2/Phase 3
- Movement Disorders · Phase 2
- Natural Childbirth · Phase 4
- Nausea · Phase 4
- Neoplasm Metastasis · Phase 2/Phase 3
- Neoplasms · Phase 4
- Olanzapine · Phase 3
- Parturition · Phase 4
- Pharmacogenetics · Phase 1
- Placebos · Phase 1
- Postoperative Complications · Phase 4
- Postoperative Nausea and Vomiting · Phase 4
- Psychiatry · Phase 4
- Psychology, Clinical · Phase 3
- Psychomotor Agitation · Phase 4
- Psychomotor Performance · Phase 3
- Psychophysiologic Disorders · Phase 3
- Respiration, Artificial · Phase 2
- Schizophrenia Spectrum and Other Psychotic Disorders · Phase 4
- Stress Disorders, Post-Traumatic · Phase 4
- Terminally Ill · Phase 2
- Therapeutic Equivalency · Phase 1
- Tobacco Use Disorder · Phase 1
- Ventilator Weaning · Phase 2
- Vomiting · Phase 4
Mechanism of action
- Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
- D2-like dopamine receptorINVERSE AGONIST
D2-like dopamine receptor inverse agonist
Approval history
- approvedPriority reviewApr 12, 1967
Chemistry & pharmacology
SMILES
O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1- Mol. weight
- 375.87 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- WikipediaLais ↗
- ChEMBLCHEMBL54 ↗
- NCATSJ6292F8L3D ↗
- WikipediaHaloperidol ↗
- ChEMBLCHEMBL1200986 ↗
- ChEMBLCHEMBL4297147 ↗
- ChEMBLCHEMBL2096643 ↗
Also known as
- 1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine
- 1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine
- 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
- 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
- 4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
- 4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
- 4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
- 4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
- 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
- 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
- aloperidin
- dolpin
- dozic
- dozic
- fortunan
- fortunan
- haldol
- haldol
- haldol
- haldol
- haldol dec
- haldol dec
- haldol decanoate
- haldol solutab
- haldol solutab
- haloperidol
- haloperidol
- haloperidol
- haloperidol
- haloperidol
- haloperidol
- haloperidol
- haloperidol
- haloperidol
- haloperidol
- haloperidol
- haloperidol decanoate
- haloperidol decanoate
- haloperidol decanoate
- haloperidol decanoate
- haloperidol decanoate
- haloperidol decanoate
- haloperidol intensol
- haloperidol intensol
- haloperidol lactate
- haloperidol lactate
- haloperidol lactate
- haloperidol lactate
- haloperidolum
- haloperidolum
- haloperin
- kentace
- keselen
- lais
- mcn-jr-1625
- mcn-jr-1625
- r-13672
- r-13672
- r-1625
- r-1625
- serenace
- serenace
- sigaperidol
- γ-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone
- γ-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07246187 | Phase 3 | Nov 6, 2025 | Mercy Bon Secours Saint Vincent Medical Center |
| NCT07109245 | Phase 4 | Sep 1, 2025 | The Physicians' Services Incorporated Foundation, University of Toronto |
| NCT06993194 | N/A | Jun 15, 2025 | Benha University |
| NCT07087925 | N/A | Jan 15, 2025 | Universitas Sumatera Utara |
| NCT06218524 | Phase 2 | Dec 1, 2024 | Southern Medical University |
| NCT06395428 | Phase 4 | Jul 9, 2024 | Western Michigan University |
| NCT06370442 | Phase 3 | Jun 1, 2024 | State University of New York, Syracuse |
| NCT06428084 | Phase 2 | Nov 1, 2023 | Padjadjaran University |
| NCT05690698 | Phase 3 | Apr 9, 2023 | Alexandria University, Suez Canal University |
| NCT05803642 | Phase 3 | Mar 28, 2023 | Qilu Pharmaceutical Co., Ltd. |
| NCT05431595 | Phase 2/Phase 3 (Phase 3) | Dec 30, 2022 | State of Texas, University of Texas at Houston |
| NCT06168773 | Phase 2/Phase 3 (Phase 3) | Nov 1, 2022 | Ain Shams University |
| NCT04833023 | Phase 3 | Nov 1, 2021 | Nanyang Technological University |
| NCT05106205 | Phase 1 | Oct 26, 2021 | Dong-A Pharmaceutical |
| NCT04750395 | Phase 2 | Sep 1, 2021 | HCA Hospice Care |
| NCT05065567 | Phase 2 | Aug 30, 2021 | The Spectrum Health Group |
| NCT04715230 | Phase 2 | Jun 30, 2021 | InterveXion Therapeutics, LLC, National Institute on Drug Abuse (NIDA) |
| NCT04764344 | Phase 4 | Apr 1, 2021 | Western Michigan University |
| NCT06014606 | N/A | Mar 1, 2021 | Maastricht University |
| NCT04529226 | Phase 2 | Sep 30, 2020 | Andalusian Health Service, Fundación Pública Andaluza |
Organizations
Research & Development (176)
Marketing (64)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ANDA Repository | For profit | MKTG | Jan 2, 1987 |
| AbbVie | For profit | MKTG | Jul 1, 2022 |
| Abraxis | For profit | MKTG | Jan 20, 1987 |
| Actavis | For profit | MKTG | Nov 2, 1995 |
| Actavis | For profit | SYN | Jul 1, 2022 |
| AiPing Pharm Inc | For profit | MKTG | Feb 17, 1987 |
| Akorn, Inc. | For profit | MKTG | Sep 6, 2017 |
| Alpharma | For profit | MKTG | — |
| Appco Pharma | For profit | MKTG | Jan 8, 2020 |
| Athenex, Inc. | For profit | MKTG | — |
| Aurobindo Pharma | For profit | MKTG | Apr 19, 2024 |
| Baxalta | For profit | MKTG | Aug 25, 2004 |
| Boston Scientific Corporation | For profit | MKTG | — |
| Caplin Point Laboratories | For profit | MKTG | May 13, 2025 |
| Chartwell Pharmaceuticals | For profit | MKTG | Nov 17, 1986 |
| Cycle Pharmaceuticals Ltd. | For profit | MKTG | Feb 17, 1987 |
| Cycle Pharmaceuticals Ltd. | For profit | SYN | Feb 17, 1987 |
| Duramed Research | For profit | MKTG | Dec 4, 1986 |
| Epic Pharma Llc | For profit | MKTG | Sep 6, 2017 |
| Fosun | For profit | MKTG | Sep 29, 2004 |
| Fresenius | For profit | MKTG | Dec 19, 1997 |
| Gland Pharma Ltd | For profit | MKTG | Aug 25, 2004 |
| Gland Pharma Ltd | For profit | SYN | May 12, 2017 |
| Hikma | For profit | MKTG | Apr 12, 1988 |
| Hikma | For profit | SYN | Apr 12, 1988 |
| Hospira | For profit | MKTG | Feb 9, 2000 |
| Innogenix | For profit | MKTG | Jan 2, 1987 |
| Johnson and Johnson | For profit | NDA2 | May 18, 1971 |
| Johnson and Johnson | For profit | NDA | Apr 12, 1967 |
| Johnson and Johnson | For profit | MKTG | Apr 12, 1967 |
| Lannett Company, Inc. | For profit | MKTG | Sep 28, 1993 |
| Lederle | For profit | MKTG | — |
| MSN Laboratories | For profit | MKTG | Nov 18, 2022 |
| Mankind Pharma | For profit | MKTG | May 23, 2023 |
| Marsam Pharmaceuticals | For profit | MKTG | Feb 25, 1993 |
| Meitheal | For profit | MKTG | Jul 26, 2021 |
| Morton Grove Pharmaceuticals | For profit | MKTG | — |
| Mylan | For profit | MKTG | Jun 10, 1986 |
| Mylan | For profit | SYN | Feb 28, 2000 |
| Novartis | For profit | MKTG | Jun 24, 2005 |
| Par Pharmaceuticals | For profit | MKTG | — |
| Pharmaceutical Associates | For profit | MKTG | Feb 26, 1993 |
| Puracap Pharmaceutical | For profit | MKTG | Nov 3, 1986 |
| Quantum Pharmaceutical | For profit | MKTG | — |
| Rubicon Research | For profit | MKTG | Jan 31, 2024 |
| Rubicon Research | For profit | SYN | Jan 31, 2024 |
| SOLOPAK | For profit | MKTG | — |
| Sagent Pharmaceuticals, Inc. | For profit | MKTG | Sep 2, 2011 |
| Sagent Pharmaceuticals, Inc. | For profit | NDA2 | — |
| Sandoz | For profit | MKTG | Nov 17, 1986 |
| Sandoz | For profit | SYN | Jun 24, 2005 |
| Sciegen Pharmaceticals | For profit | MKTG | Feb 17, 1987 |
| Smith & Nephew | For profit | MKTG | — |
| Somerset Pharmaceuticals | For profit | MKTG | Jul 3, 2018 |
| Strides Pharma Science | For profit | MKTG | Nov 3, 1986 |
| Teva | For profit | MKTG | Aug 25, 1987 |
| Teva | For profit | SYN | Dec 1, 1988 |
| Teva | For profit | SYN | May 11, 1999 |
| Upsher-Smith Laboratories | For profit | MKTG | Jan 8, 2020 |
| Vintage | For profit | MKTG | Nov 3, 1986 |
| Watson Pharmaceuticals | For profit | MKTG | Mar 6, 1987 |
| West-Ward Pharmaceutical | For profit | MKTG | Jan 30, 1998 |
| Zydus Discovery DMCC | For profit | MKTG | Nov 29, 2007 |
| Zydus Discovery DMCC | For profit | SYN | Oct 22, 2019 |